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Symptomatic treatment during the dementia stage of Alzheimer’s disease(AD) cannot delay or halt the progression
of this disease. Therefore, prevention in the preclinical stage is likely the most effective way to decrease the
incidence of this age-associated neurodegenerative condition, and its associated burden for individuals and society.
Age, gender, family history, ApoE4, systolic blood pressure, body mass index, total cholesterol level and physical
activity are all used as component of dementia risk score. There have been numerous challenges in conducting
primary prevention trials in AD. Enrichment strategies for prevention studies include studying those subjects with
more risk factors for AD, such as older age, those with a positive family history of late onset AD, and those who are
ApoE4 positive. Each of these strategies is designed to increase the probability of developing AD thereby
decreasing the sample size or the duration of follow up. Another strategy would be to target directly the
pathophysiology of AD in its preclinical stages and use the biomarkers in prevention trial as surrogate markers. This
will be done first in carriers of dominantly inherited early onset AD. As this research takes place networks of
memory clinics must prepare to transfer new knowledge to persons interested in a preventive approach to AD.
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Alzheimer disease (AD) is characterized by accumulation
of amyloid plaques, neurofibrillary tangles and neuronal
depletion associated with progressive deterioration of
cognition and functional status [1]. AD is a catastrophic
disease and symptomatic treatment (e.g. donepezil, rivas-
tigmine, galantamine, memantine) during the different
stages of dementia can only mildly ameliorate the symp-
toms and cannot delay or halt the progression of this
disease, since extensive brain damage has already oc-
curred prior to the dementia phase of AD [2]. Therefore,
prevention in the preclinical stage is likely the most
effective way to decrease the incidence of this age-
associated neurodegenerative condition, and its asso-
ciated burden for individuals and society [3]. There is
great interest in prevention studies as a way to reduce
the incidence and prevalence of dementias. This review
will summarize the results of recent researches and out-
line some prevention strategies of AD for future research.* Correspondence: serge.gauthier@mcgill.ca
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Numerous risk factors for AD have been identified by
epidemiologic studies [4,5]. Everyone is at risk if living
long enough (33% of individuals have AD over age 85),
but some persons are more at risk than others because
of their family history (Table 1). Family history in first-
degree relatives is the main factor, and the age of onset
of the family member matters as well: apoE4 genotype is
more likely to be a factor if one of parent had AD at age
70 rather than at age 85[6].
Other known risks include subjective cognitive com-
plaints [7] and demonstrable decline on serial cognitive
testing even if still within the normal range considering
age and education [8]. Another approach has been the
assessment of a variety of risk factors in mid-life, giving
them relative weights, and adding them up in a “Demen-
tia Risk Score” [5], as summarized in (Mid-life dementia
risk score [modified from 5]).
Mid-life dementia risk score [modified from 5]
• Age at time of initial assessment
• Formal education level
• Gender
• Systolic blood pressurel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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• Total cholesterol level in blood
• Level of physical activity
The new factors in the risk assessment towards AD are
biomarkers: amyloid deposition evaluated by amyloid PET
imaging and/or a reduction in levels of Aß42 in the cere-
brospinal fluid (CSF), and neurodegeneration demon-
strated by CSF, functional and structural imaging (e.g. tau
of CSF, [18 F]-fluorodeoxyglucose positron emission tom-
ography (FDG-PET) and structural MRI) [9]. The relative
weight of these risk factors is still unknown, but at least
33% of cognitively normal persons over age 65 are “bio-
marker positive”. A new diagnostic category has been pro-
posed by a National Institute on Aging (NIA) task force
for such individuals, as summarized in Table 2 [10].
Prevention of AD
There have been numerous difficulties in conducting pri-
mary prevention trials in AD because of the unclear
pathophysiological mechanism of AD, the difficulty in ac-
curate selection of the target population, the need for a
large sample size, long duration of follow up, the high cost
of the prevention study, adverse events of the prevention
drugs being studied and the related ethical issues [11-15].
Who should be enrolled in the primary prevention trials
remains a very important but complex issue. The target
populations of primary prevention are usually the healthy
elderly. The subjects enrichment strategies include study-
ing those subjects with more risk factors for AD, such as
older people, those with a positive family history of AD,
and those who are Apo E4 positive [11]. Each of these
strategies is designed to increase the probability of devel-
oping AD thereby decreasing the sample size or the dur-
ation of follow up[11,16]. Another group of interest are
persons with memory complaints but no measurable cog-
nitive impairment (subjective cognitive impairment or “pre-
MCI”), at higher risk of progression to dementia [17].
Non-pharmacological interventions
Non-pharmacological interventions are possible: life
style changes are of great interest to modify risk factors
(predominantly vascular) and enhance protective factorsTable 1 Proposed gradation of risk for AD in
asymptomatic persons
• Basic risk (age)
• Vascular risk factors
• Family history of AD in first degree relatives but of late onset (>75)
• Family history of younger onset (65–75)
• Family history and ApoE4 +
• Biomarker + (ex. PET amyloid positive scan)
• Autosomal dominant mutation carrier(predominantly physical exercises, cognitive stimulation,
healthy diet). Ongoing studies such as the the Multidomain
Alzheimer Prevention Trial (MAPT) in Toulouse, France,
combine omega-3 supplements with multi-domain inter-
ventions [18].
Pharmacological interventions
Different risk and protective factors have been associated
with AD, particularly in mid-life, and are amenable to a
preventive approach [5]. Some prospective randomized
studies targeting vascular risk factors such as systolic
hypertension have demonstrated a reduction in the
prevalence of dementia [19] but others not [20]. These
equivocal findings may be explained in part by the vari-
able effects of antihypertive drugs on pathways related
to AD, but they have lead to a lack of endorsement by a
US task force for the control of systolic hypertension as
well as for any other life-style change as a preventive ap-
proach to AD [21] Nevertheless the weight of the evi-
dence is that prevention of stroke is a good strategy to
prevent dementia, either by control of vascular risk fac-
tors or by optimal post-stroke management.
Another strategy would be to target directly the patho-
physiology of AD in its preclinical stages [22]. There are
many possible pathophysiological targets for primary
prevention in AD, including amyloid plaques, soluble
amyloid, neurofibrillary tangles, loss of neurotransmit-
ters, synapse loss, inflammation, and oxidative stress
[11]. Table 3 lists some of these pathophysiological fac-
tors and potential drug treatments [2].
Biomarker positivity can be important in deciding
what population to enroll in a prevention study: more
risk of progression to dementia will shorten the study
but will limit the applicability of findings to the popula-
tion as a whole [15,22]. Diagnostic biomarkers play an
important role in population enrichment by refining se-
lection criteria, stratifying populations and increasing
the statistical power of trials. Endpoint biomarkers may
be used as outcome measures to monitor the rate of dis-
ease progression and detect treatment effects of drugs
[23].
The side effects of drugs are not negligible, particularly
in asymptomatic persons. These risk/benefit considera-
tions are very important to research ethics boards and
regulators: “safety must be the primary consideration
since an agent that will be administered to thousands of
healthy normal individuals, many of whom will never
develop disease, must be remarkably free of side effects”
[24].
Aims in prevention studies for AD
Delaying biomarkers changes
The Alzheimer Disease Neuroimaging Initiative (ADNI)
has demonstrated that biomarkers change over time in a
Table 2 Asymptomatic persons with positive biomarkers of AD [modified from 10]
Stage Biomarkers or evidence
Aß (amyloid PET
or CSF)




asymptomatic cerebral amyloidosis (ACA) positive negative negative
ACA+neuronal injury (NI) positive positive negative
ACA+NI + subtle cognitive decline positive positive positive
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studies looking at delaying biological progression over a
relatively short time (12 to 18 months). For instance in
early MCI (EMCI) there is already amyloid deposition
but little PET-FDG changes and no atrophy on MRI
[25]. Progression to late MCI (LMCI) will likely correlate
with worsening of PET-FDG and early atrophy on serial
MRI. This type of study would be considered as proof-
of-concept and would be supportive for longer and lar-
ger clinical trials. Shorter (12 months) studies could even
be done in APP or presenilin mutation carriers who are
within 5 years of their expected time of dementia (ETD)
based on their family history [16].Delaying cognitive decline
Delaying decline of cognition using a standardized cognitive
measure may be a valid primary outcome in primary or sec-
ondary prevention studies [15]. The CogState appears to be
of interest for epidemiological studies in older people [26]
and in MCI [27] The episodic memory decline measured
by the CogState correlates with findings on amyloid PET
imaging [28], thus bridging cognition and biomarkers in
pre-dementia stages of AD.Delaying dementia
The studies comparing Ginkgo Biloba in France [29]
and in the USA [30] are good examples of randomized
studies where time to dementia was the primary out-
come. The low incidence rate of dementia caused the
US study to be prolonged from the original five years
to seven. Thus although having a high face validity, a
delay of incident dementia may not be the ideal out-
come because of the duration of studies and the need
for a conversion committee on top of an experienced





inadequate synaptic plasticityIn the future, primary prevention trials of AD will
still need to deal with the issues of enrollment of target
population, safety of drugs, cost, and the length and out-
come of follow up. Drugs chosen for testing in primary
prevention trials should be demonstrated to be safe when
administered to normal elderly [11]. Although time to
diagnosis of dementia is at present still the primary out-
come measure in the traditional prevention clinical trials
of AD and there are no biomarkers replacing the clinical
outcome of dementia or cognitive decline, biomarkers
may assist or even become surrogate outcomes in the clin-
ical trial of AD in the future [12].Clinical application of prevention
There is a need for a structured approach to the preven-
tion of AD as new data becomes available. Groups of
persons at different level of risk are already seeking ad-
vice from their family doctor and memory clinics. The
baby boomers may flood the resources of specialized
centers for AD who are currently responsible for the
diagnosis and symptomatic treatment of AD and other
dementias, and who will also have to deal with the use
of disease-modifying drugs in the near future, some re-
quiring monthly intravenous infusions. Hopefully family
doctors with interest in prevention of heart disease and
stroke will also be interested in AD prevention, since
these conditions share many risk factors.Conclusions
The prevention of AD require large investment of time
and money, but the return on investment may be huge,
considering the projections of costs for patients with de-
mentia in the near future. Regular meetings of clinical
trialists and epidemiologists will facilitate the develop-
ment of methodology for successful prevention studies,s
Potential drug treatments
beta and gamma secretase inhibitors active and passive immunotherapy
methylene blue, lithium, memantine
naproxen
probuchol
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Association [31].
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